Page 69 - IMO-1-1

Innovative Medicines & Omics Antioxidant nanomedicines for therapies

363. Nguyen DD, Luo LJ, Yang CJ, Lai JY. Highly retina- 374. Caprara C, Grimm C. From oxygen to erythropoietin:
permeating and long-acting resveratrol/metformin Relevance of hypoxia for retinal development, health and
nanotherapeutics for enhanced treatment of macular disease. Prog Retin Eye Res. 2012;31(1):89-119.
degeneration. ACS Nano. 2023;17(1):168-183.
doi: 10.1016/j.preteyeres.2011.11.003
doi: 10.1021/acsnano.2c05824
375. Blasiak J, Petrovski G, Vereb Z, Facsko A, Kaarniranta K.
364. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles Oxidative stress, hypoxia, and autophagy in the neovascular
prevent retinal degeneration induced by intracellular processes of age-related macular degeneration. Biomed Res
peroxides. Nat Nanotechnol. 2006;1(2):142-150. Int. 2014;2014:768026.
doi: 10.1038/nnano.2006.91 doi: 10.1155/2014/768026
365. Mitra RN, Gao R, Zheng M, et al. Glycol chitosan 376. Campochiaro PA. Targeted pharmacotherapy of
engineered autoregenerative antioxidant significantly retinal diseases with ranibizumab. Drugs Today (Barc).
attenuates pathological damages in models of age-related 2007;43(8):529-537.
macular degeneration. ACS Nano. 2017;11(5):4669-4685. doi: 10.1358/dot.2007.43.8.1120868
doi: 10.1021/acsnano.7b00429 377. Stewart MW. Aflibercept (VEGF-TRAP): The next anti-VEGF
366. Badia A, Duarri A, Salas A, et al. Repeated topical drug. Inflamm Allergy Drug Targets. 2011;10(6):497-508.
administration of 3 nm cerium oxide nanoparticles doi: 10.2174/187152811798104872
reverts disease atrophic phenotype and arrests
neovascular degeneration in AMD mouse models. ACS 378. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular
Nano. 2023;17(2):910-926. pharmacokinetics of bevacizumab after a single intravitreal
injection in humans. Am J Ophthalmol. 2008;146(4):508-512.
doi: 10.1021/acsnano.2c05447
doi: 10.1016/j.ajo.2008.05.036
367. Sarna T. Properties and function of the ocular melanin--a
photobiophysical view. J Photochem Photobiol B. 379. Xue B, Ge M, Fan K, et al. Mitochondria-targeted nanozymes
1992;12(3):215-258. eliminate oxidative damage in retinal neovascularization
disease. J Control Release. 2022;350:271-283.
doi: 10.1016/1011-1344(92)85027-r
doi: 10.1016/j.jconrel.2022.08.026
368. Sarna T, Burke JM, Korytowski W, et al. Loss of melanin
from human RPE with aging: possible role of melanin 380. Zhang R, Xue B, Tao Y, et al. Edge-site engineering of
photooxidation. Exp Eye Res. 2003;76(1):89-98. defective Fe-N(4) nanozymes with boosted catalase-
like performance for retinal vasculopathies. Adv Mater.
doi: 10.1016/s0014-4835(02)00247-6 2022;34(39):e2205324.
369. Kwon YS, Zheng M, Zhang AY, Han Z. Melanin-like doi: 10.1002/adma.202205324
nanoparticles as an alternative to natural melanin in
retinal pigment epithelium cells and their therapeutic 381. Zhang R, Chen L, Liang Q, et al. Unveiling the active sites
effects against age-related macular degeneration. ACS on ferrihydrite with apparent catalase-like activity for
Nano. 2022;16(11):19412-19422. potentiating radiotherapy. Nano Today. 2021;41:101317.
doi: 10.1016/j.nantod.2021.101317
doi: 10.1021/acsnano.2c09087
382. Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367-1377.
370. Truong A, Wong TY, Khachigian LM. Emerging therapeutic
approaches in the management of retinal angiogenesis and doi: 10.1016/S0140-6736(10)61423-7
edema. J Mol Med (Berl). 2011;89(4):343-361.
383. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and
doi: 10.1007/s00109-010-0709-z treatment of glaucoma: A review. JAMA. 2014;311(18):1901-1911.
371. Hartnett ME, Penn JS. Mechanisms and management of doi: 10.1001/jama.2014.3192
retinopathy of prematurity. N Engl J Med. 2012;367(26):2515-2526.
384. Goyal A, Srivastava A, Sihota R, Kaur J. Evaluation of
doi: 10.1056/NEJMra1208129 oxidative stress markers in aqueous humor of primary
open angle glaucoma and primary angle closure glaucoma
372. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. patients. Curr Eye Res. 2014;39(8):823-829.
Lancet. 2010;376(9735):124-136.
doi: 10.3109/02713683.2011.556299
doi: 10.1016/S0140-6736(09)62124-3
385. Inman DM, Lambert WS, Calkins DJ, Horner PJ. α- lipoic
373. Campochiaro PA. Ocular neovascularization. J Mol Med acid antioxidant treatment limits glaucoma-related
(Berl). 2013;91(3):311-321.
retinal ganglion cell death and dysfunction. PLoS One.
doi: 10.1007/s00109-013-0993-5 2013;8(6):e65389.

Volume 1 Issue 1 (2024) 63 doi: 10.36922/imo.2527